Fig. 1 · Structure

Documents & Downloads

Gallic Acid

Cat. No. A12055 CAS 149-91-7

COX-2 inhibitor

Gallic acid is a trihydroxybenzoic acid found in many plants as either the free acid or in the esterified form of gallotannins and ellagitannins. Gallic acid is an antioxidant which can inhibit both COX-2.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
COX-2  
Microbial Metabolite  
Human Endogenous Metabolite  

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 0.4 mM Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay [PMID: 27162124]
A549 IC50 0.4 mM Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay [PMID: 27162124]
A549 IC50 0.4 mM Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay [PMID: 27162124]
CCRF-CEM IC50 > 200 μM Cytotoxicity against human CCRF-CEM cells after 48 hrs by neutral red assay [PMID: 24568614]
CCRF-CEM IC50 > 50 μM Cytotoxicity against human CEM cells after 24 hrs by MTT assay [PMID: 18295493]
CCRF-CEM IC50 > 50 μM Cytotoxicity against human CEM cells after 72 hrs by MTT assay [PMID: 18295493]
CCRF-CEM EC50 > 50 μM Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay [PMID: 25617695]
CCRF-CEM EC50 > 50 μM Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay [PMID: 25617695]
Erythrocyte IC50 0.59 mM Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me [PMID: 29631958]
Erythrocyte IC50 0.74 mM Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet [PMID: 29631958]
HCT-116 IC50 41.8 μg/mL Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay [PMID: 32731188]
HeLa IC50 26.3 μg/mL Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay [PMID: 32731188]
HUVEC IC50 > 294 μM Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 48 hrs by fluorescence based assay [PMID: 37122550]
L1210 IC50 > 50 μM Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay [PMID: 18295493]
L1210 IC50 50 μM Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay [PMID: 18295493]
MCF7 IC50 17.4 μM Cytotoxicity against human ER-positive MCF7 cells assessed as decrease in cell proliferation at 12.5 to 100 uM incubated for 24 hrs [PMID: 33711444]
RAW264.7 IC50 > 50 μM Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by by Griess assay [PMID: 31419126]
RAW264.7 IC50 631.6 μM Inhibition of LPS-induced NO production in mouse RAW264.7 cells assessed as reduction in nitrite level within 24 hrs by Griess reagent method [PMID: 22560043]
RAW264.7 IC50 69.25 μM Antagonist activity at TLR2 in mouse RAW264.7 cells assessed as PAM3CSK4-induced NO production measured after 24 hrs by Griess assay [PMID: 31255924]

19 records · Scroll to view more

Gallic Acid Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Gallic Acid from 2 published references. In vitro models include human umbilical vein endothelial cell (HUVEC); J774A.1 cell. In vivo models include C57BL/6J mice.

Gallic Acid In Vitro Studies

In human umbilical vein endothelial cells, Gallic Acid pretreatment decreased overall tube length per area compared with the untreated control group. In LPS-primed J774A.1 cells, Gallic Acid dose-dependently suppressed caspase 1 p20 release compared with the LPS plus ATP group. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reduced Endothelial Tube Length

Cell-based study · human umbilical vein endothelial cell (HUVEC) [1]

Human umbilical vein endothelial cells were pretreated with Gallic Acid at 5, 10 or 15 μg/ml for 24 h. Tube length per area decreased to ~16.5%, 15.3% and 30.3% of the untreated control group, respectively.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
overall tube length per areatube length per area ~16.5%, 15.3% and 30.3% of the control group[1]

Literature-Reported Treatment Conditions

Treatment concentration
5, 10 or 15 μg/ml
Exposure duration
pretreated with 5, 10 or 15 μg/ml gallic acid for 24 h
Vehicle
dimethyl sulfoxide
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Gallic Acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Materials (S2); Materials and methods > Tube formation assay (S40); Results > Gallic acid inhibits angiogenesis (S76, S77); Figure 3 legend (S100, S101)

overall tube length per area: overall tube length per area; comparator: untreated control group — Materials and methods > Tube formation assay (S40); Results > Gallic acid inhibits angiogenesis (S77)

Dose-Dependent Suppression of Caspase Release

Cell-based study · J774A.1 cell [2]

LPS-primed J774A.1 cells were treated with Gallic Acid at 20, 40, 80 µM. Gallic Acid dose-dependently suppressed the release of caspase 1 p20 compared with the LPS plus ATP group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
release of caspase 1 p20Reported result gallic acid dose-dependently suppressed the release of caspase 1 p20[2]

Literature-Reported Treatment Conditions

Treatment concentration
20, 40, 80 µM
Exposure duration
primed with LPS (500 ng/ml) for 4 h, and gallic acid or the indicated compound was added for another 30 min
Co-treatment
Other interventions in this design: LPS 500 ng/ml; ATP 3 mM. Compound effect isolated by the comparison: compared with LPS plus ATP group.
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Gallic Acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cell Culture and Stimulation (S25); Results > Gallic Acid Inhibits Cell Death in Lipopolysaccharide-Primed and Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3 Inflammasome Activator-Treated Macrophages (S110); Results > Gallic Acid Suppresses Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3 Inflammasome Activation and Pyroptosis (S124)

release of caspase 1 p20: release of caspase 1 p20; comparator: LPS plus ATP group — Results > Gallic Acid Suppresses Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3 Inflammasome Activation and Pyroptosis (S124)

Gallic Acid In Vivo Studies

Gallic Acid was administered to C57BL/6J mice at 100 mg/kg by intra-articular injection, and joint swelling was measured at different time points. Gallic Acid reduced knee-joint swelling compared with MSU-treated mice. [2]

Reduced Knee-Joint Swelling in Mice

Animal study · C57BL/6J mice [2]

C57BL/6J mice received Gallic Acid at 100 mg/kg by intra-articular injection. Gallic Acid reduced knee-joint swelling compared with MSU-treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Joint swelling was measured at different time pointsReported result gallic acid could effectively reduce knee-joint swelling compared with MSU-treated mice[2]

Conditions shared by the study groups

Route
intra-articular injection
Treatment course
24 h
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Gallic Acid 100 mg/kgMSU-treated micegallic acid could effectively reduce knee-joint swelling compared with MSU-treated mice[2]
Gallic Acid 100 mg/kg
Model: C57BL/6J mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Gallic Acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Monosodium Urate-Induced Arthritis (S84); Results > Gallic Acid Mitigates Monosodium Urate-Induced Inflammation in Gouty Mice (S169); Figure 6 legend (S226, S228)

Joint swelling was measured at different time points: Joint swelling was measured at different time points; comparator: MSU-treated mice — Results > Gallic Acid Mitigates Monosodium Urate-Induced Inflammation in Gouty Mice (S169); Figure 6 legend (S228)

Gallic Acid 100 mg/kg · Materials and Methods > Monosodium Urate-Induced Arthritis (S84); Results > Gallic Acid Mitigates Monosodium Urate-Induced Inflammation in Gouty Mice (S169); Figure 6 legend (S226)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 149-91-7
Applications

COX-2 inhibitor

Formula C7H6O5
Molecular Weight 170.1
Synonyms NSC 674319; NSC 20103
SMILES
OC1=C(O)C(O)=CC(C(O)=O)=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 32 mg/mL (188.09 mM)
Water 7 mg/mL (41.14 mM)
Ethanol 32 mg/mL (188.09 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Gallic Acid Research References

  1. [1] Zhao B, Hu M. Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells. Oncol Lett (2013). PMID: 24843386 DOI: 10.3892/ol.2013.1632 Source material
  2. [2] Lin Y, Luo T, Weng A, et al. Gallic Acid Alleviates Gouty Arthritis by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis Through Enhancing Nrf2 Signaling. Front Immunol (2020). PMID: 33365024 DOI: 10.3389/fimmu.2020.580593 Source material

Added to your cart

View Cart Checkout
Loading...